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Abstract 
Background: The precise function of tissue factor (TF) expressed by dendritic cells 
(DC) is uncertain. As well as initiating thrombin generation it can signal through 
protease activated receptor (PAR)-2 when complexed with factor VIIa. 
Methods: We investigated the expression and function of TF on mouse bone marrow 
(BM)-derived DC.  
Results: 20% of BM-derived DC expressed TF, which did not vary after incubation 
with LPS or dexamethasone (DEX). However, the procoagulant activity of DEX-
treated DC in recalcified plasma was 30 fold less than LPS-treated DC. In antigen-
specific and allogeneic T cell culture experiments, the TF on DEX-DC provided a 
signal through PAR-2, which contributed to the reduced ability of these cells to 
stimulate CD4+ T cell proliferation and cytokine-production.  In vivo, an inhibitory 
anti-TF Ab and a PAR-2 antagonist enhanced antigen-specific priming in two models 
where antigen was given without adjuvant, with an effect approximately 50% that 
seen with LPS, suggesting a similar mechanism was operational physiologically.   
Conclusions: These data suggest a novel TF and PAR-2 dependent mechanism on 
DEX-DC in vitro and unprimed DC in vivo that contributes to the low immunogenicity 
of these cells. Targeting this pathway has the potential to influence antigen-specific 
CD4+ T cell activation. 
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Introduction 
Initiation and propagation of the coagulation cascade in haemostasis and thrombosis 
is well characterised and results in the formation of a fibrin clot. Tissue factor (TF) is 
the physiological initiator of thrombin generation and is constitutively expressed on 
vascular adventitial cells, leading to the traditional concept that TF forms a 
‘haemostatic envelope’ to prevent bleeding from damaged vessels 1.  
TF can also be induced on inflammatory cells and has been implicated in the 
pathogenesis of a variety of diseases such as atherosclerosis, malignancy and Ab-
mediated rejection 2. Although some of these processes involve thrombosis, some of 
the effects of TF are fibrin-independent and involve signalling through protease 
activated receptors (PAR), which are cleaved by serine proteases to expose a neo-
N-terminal activating tethered ligand 3. Thrombin can cleave and activate PARs 1, 3 
& 4, whereas TF bound to factor VIIa (FVIIa) in a binary complex is capable of 
activating PAR-2 directly. PAR-2 is also cleaved by a number of other proteases 
including FXa, trypsin, proteinase 3 and mast cell tryptase. 
TF and PARs are expressed by a number of immune cells including monocytes, 
macrophages and DC 4. On antigen-primed DC, thrombin, via PAR-1 has a profound 
influence on migration through lymph nodes and subsequent spread of systemic 
inflammation in murine models of endotoxaemia and infection 5. Additionally, PAR-2 
signalling has been shown to enhance uptake of antigens, trafficking and T cell 
activation by DC 6-10. 
In this paper, we investigated the function of TF on mouse bone marrow (BM)-
derived DC, comparing DC outgrown under standard conditions with those incubated 
with either dexamethasone (DEX) or LPS. Our data suggests that, despite similar 
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expression levels of TF by all three, there is a hierarchy of procoagulant activity and 
TF expressed by dexamethasone (DEX)-treated DC appears to provide signalling 
through PAR-2 to sustain the low immunogenicity of these cells. Based on additional 
data generated in vivo, we speculate that a similar mechanism operates 
physiologically to limit CD4+ T cell priming to specific antigens encountered in the 
absence of an adjuvant. 
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Methods  
Animals 
6-8 week old BALB/c (H-2d) and C57BL/6 (H-2b) mice were purchased from Harlan 
Laboratories. Two strains expressing transgenic T cell receptors (TCR) were used to 
assess antigen-specific responses, chosen because they were available within the 
Immunology Department. The first, Marilyn, has a transgenic TCR specific for male 
HY antigen restricted by MHC class II and the second, DO11.10 has a TCR that 
recognises an OVA peptide (OVA323-339) restricted by H-2Ad. Both were kind gifts 
from Drs Jian Guo Chai and Andrew George (Imperial College London).  All 
procedures were performed in accordance with the Home Office Animals (Scientific 
Procedures) Act of 1986.  
Cell isolation and T cell assays. 
BM-derived DC were cultured as described elsewhere 11.  Briefly cells were flushed 
out from the femurs and tibiae of mice and passed through a nylon cell strainer. Red 
blood cells were lysed using ammonium-chloride-potassium buffer. After washing, 
1x106/ml cells were seeded in RPMI growth medium plus 5% supernatant from a 
GM-CSF producing hybridoma cell line. On day 3, non adherent cells were discarded 
and fresh medium was added. In some cultures, either 1µM dexamethasone (DEX) 
(Sigma-Aldrich, UK) 12 or 1µg/ml LPS (Escherichia coli serotype 0128:B12) (Sigma-
Aldrich, UK) was added on days 5 or 6.  DCs were harvested on day 7.  
T cells were isolated from the spleen and lymph nodes (mesenteric, inguinal and 
axillary). Organs were passed through a nylon cell strainer and red blood cells were 
lysed as above. Splenocytes were incubated with an Ab cocktail supplied by 
Invitrogen containing rat anti-mouse Gr, CD16/32, MHCII and CD8 antibodies for 20 
min at 4°C before washing and incubation with sheep anti-rat magnetic beads for 
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negative selection according to manufacturer’s instructions. The resulting CD4+ T 
cells were 90-95% pure. 
To assess T cell proliferation against alloantigens, 2x105 BALB/c T cells were 
stimulated with 1x104 irradiated C57BL/6 DCs in 200µl complete medium unless 
otherwise stated. To assess antigen-specific proliferation, 2x105 female Marilyn 
CD4+ T cells were stimulated with 1x104 male C57BL/6 DCs in 200µl complete 
medium. In some assays, rabbit polyclonal anti-TF Ab (American Diagnostica) or 
control rabbit Ig were added at beginning. Proliferation was measured by adding 3H-
thymidine on day four of culture and harvesting 16 to 18 hours later to determine T 
cell proliferation as assessed by incorporated radioactivity.  
Flow cytometric analysis 
All flow cytometry was performed on a FACSCalibur flow cytometer and analysed 
using Cellquest (BD BioSciences, UK) or Flojo (Treestar, USA) software. For cell 
surface analysis, the following antibodies were used; rat anti-mouse CD4, CD8, (e-
Bioscience USA) FITC-CD80 (Serotec UK), FITC-CD86 (Becton Dickinson UK); 
hamster anti-mouse FITC-CD3, FITC-CD11c, FITC-MHC II (e-Bioscience USA); 
rabbit polyclonal anti-TF, anti-TFPI (both American Diagnostica), PAR-3, PAR-4 
(Santa Cruz USA); mouse anti-PAR-1 (Becton Dickinson), PAR-2 (Santa Cruz). 
Where appropriate, the following second layers were used; Swine anti-rabbit FITC-Ig 
(Dako, Denmark); Goat anti-rabbit FITC-Ig, anti-rabbit PE-Ig (Sigma-Aldrich UK), 
anti-mouse FITC IgG (Dako); mouse anti-rat FITC-Ig (e-Bioscience). 2x105 cells 
were analysed immediately or fixed in 2% paraformaldehyde in PBS and analysed 
within three days. 
Intracellular cytokine staining as performed as previously described 13.  Briefly, cells 
were stimulated with 50ng/ml PMA (Sigma-Aldrich, UK) plus 500ng/ml ionomycin 
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(Calbiochem, Germany) for 4 hours, with 10µg/ml brefeldin A (Sigma-Aldrich) for the 
final 2 hours. All washes and incubations were done in buffer containing 0.5% 
Saponin (Sigma-Aldrich). Cells were stained with rat anti-IFNγ, IL-4 or IL-10 (all from 
BD Pharmingen USA) 
RNA extraction and RT-PCR 
Between 5x106 and 1x107 cells were washed thoroughly with PBS before RNA was 
extracted using phenol and chloroform and re-suspended in RNAse-free water 
(Sigma-Aldrich).  RNA was assessed using agarose gel analysis and Quanti-iT 
Ribogreen RNA reagent and kit (Invitrogen, UK). RT-PCR was peformed using 
reagents from Applied Biosystems, USA, including primers for PARs 1-4 and beta-
actin. All PCR products were run on 1% agarose gel. 
Clotting Assay  
Mouse acetone brain extract (Sigma, UK), used as a standardized source of TF and 
all other reagents were suspended in 50mM Tris-HCL, 150 mM NaCl and 1 mg/ml 
human albumin pH 7.4. For test samples, cells were suspended at a concentration of 
1x107/ml. Serial dilutions of brain extract (in 80μl) or 1x107 cells /ml (80μl) were 
mixed in a glass tube with 80μl phospholipid and 80μl pooled normal mouse plasma 
at 37°C for one minute. To start the clotting assay 80μl 65mM CaCl2 was added, 
and, whilst being continuously agitated, the time for a clot to form in the tube was 
measured. In some assays, rabbit polyclonal anti-TF Ab or control rabbit Ig were 
added at beginning. All samples performed in triplicate. A standard curve generated 
from the TF in mouse brain extract was used to measure relative TF function in the 
test samples.  
In vivo antigen specific T cell sensitisation 
Page 8 of 52Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 9
Cells from lymph nodes and spleen of naive DO11.10 mice were labelled with 2.5µM 
CFSE (Cambridge Biosciences, UK) using standard protocols.  1x107 cells were 
injected into the tail vein of BALB/c mice.  24 hours later, the mice were given an i.p. 
injection of either saline, 250µg anti-TF Ab 14, control rabbit Ig, 25µg LPS 
(Escherichia coli serotype 0127:B8) (Sigma-Aldrich, UK)  or LPS alone followed by 
5mg whole OVA.  72 hours later, lymph node (cervical, axillary, brachial and 
inguinal) cells were harvested for analysis of proliferation and IFN-γ, IL-4 and IL-10 
production by flow cytometry. 
Contact sensitivity responses 
On day 0, C57BL/6 mice were sensitised by application of 5% oxazalone in ethanol 
and acetone (4:1, 50ul) to the shaved abdomen. At the same time mice were 
injected i.p. with either 100µl saline control, 1uM/kg PAR 2 agonist or 100uM/kg 
PAR-2 antagonist. Mice were re-challenged on day 5 by applying 1% oxazolone in 
olive oil and acetone (4:1, 10ul) to the right ear, whereas the left ear was painted 
with vehicle alone. Ear thickness was measured using a digitial micrometer. 
Measurements were done on day 5 as a baseline and then 24 and 48 hours 
following ear painting. 
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Results 
 
TF expression and procoagulant function on in-vitro cultured DC 
C57BL/6 BM-derived DC (>85% CD11c+) were examined by flow cytometry.  Figure 
1 illustrates the expression of MHC class II, CD80 and CD86 by cells grown under 
three different conditions. As expected, DEX-treated DC expressed low levels of 
MHC II and co-stimulatory molecules whereas LPS-treated DC had higher 
expression.  DC cultured without either DEX or LPS (‘untreated’) had an intermediate 
phenotype. Subpopulations of DC from all three conditions expressed detectable TF 
antigen on their cell surface, representing 15-20% of the CD11c+ cells, with similar 
population MFI (figure 1B-D), suggesting similar levels of TF expression.  Similar 
results were obtained with DC grown from BALB/c mice (data not shown).  
In clotting assays using re-calcified mouse plasma, addition of all three DC 
populations promoted shorter clotting times compared to the ‘no cells’ control, with a 
hierarchy of clotting times (LPS<untreated<DEX) (figure 2A), each of which was 
prolonged by an inhibitory anti-TF Ab (figure 2B) suggesting that there were 
significantly different levels of procoagulant TF present on each type of DC. This was 
confirmed when the relative TF procoagulant activity on each was calculated (Figure 
2C).  In these experiments, the time to clot spontaneously in glass tubes (‘no cells’ in 
Figure 2A) represents the clotting induced by the (TF-independent) contact activated 
pathway. These data indicated that a greater proportion of TF on DEX-treated DC 
was in the non-procoagulant or ‘encrypted’ form.  There were no detectable 
differences in annexin V binding, protein disulphide isomerase or murine tissue 
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factor pathway inhibitor expression by any of the DC used in these assays (data not 
shown).  
 
Biological activity of TF on DEX-treated DC  
To investigate whether TF on DEX-treated DC had a biological function, male DCs 
were co-cultured with naïve CD4+ T cells from female Marilyn mice, which possess a 
transgenic TCR that recognises the male HY antigen restricted by MHC class II. 
Compared to DEX-treated DC incubated with isotype control Ig, DC incubated with 
inhibitory anti-TF Ab stimulated significantly greater proliferation (figure 2D). These 
experiments were repeated with allogeneic DC and WT CD4+ T cells, with similar 
results (figure 2E), suggesting that the effect was not due to antigen processing. The 
same Ab did not enhance the near-maximal proliferation induced by untreated DC 
(figure 2F) and had no impact on proliferation of CD8+ T cells induced by DEX-
treated DC (figure 2G). These results indicated that inhibiting TF on DEX-DC 
specifically enhanced proliferation by CD4+ T cells and suggested that the TF on 
DEX-DC was acting to limit the capacity of these cells to induce CD4+ T cell 
proliferation.  
The TF- FVIIa complex can cleave and activate PAR-2 signalling 15. Analysis of PAR 
expression by DEX-DC revealed transcripts for all PARs (figure 3A), but only PAR-2 
and PAR-4 were detectable on the cell surface by flow cytometry (figure 3B), which 
may reflect known differences in the importance of mRNA stabilisation for expression 
of different PARs 16. To address whether the effect of TF was due to signalling 
through PAR, agonist or antagonist peptides were added to DEX-DCs, prior to co-
culture with CD4+ T cells. Figures 3C&D show that, in contrast to when PAR-1 or -4 
agonists were used, a selective PAR-2 agonist inhibited the effect of the anti-TF Ab, 
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indicating that PAR-2 activation was able to compensate for the inhibition of TF when 
Ab was present.  In contrast, a PAR-2 antagonist enhanced the proliferative capacity 
of DEX-treated DC to the same extent as the anti-TF Ab (figure 3E), suggesting that 
it had the same functional effect as the Ab.  These data are consistent with the 
hypothesis that the (mostly) encrypted TF on DEX-treated DC influences the 
capacity to stimulate T cells through activation of PAR-2. 
 
Inhibition of TF/PAR-2 signaling enhances T cell priming in vivo 
To assess whether any of this was relevant in vivo, lymph node and spleen cells 
from naïve DO11.10 mice were isolated and CFSE labelled. T cells from these mice 
possess a transgenic T cell receptor that recognises an OVA peptide (OVA323-339) 
restricted by H-2Ad [372- Murphy KM Science 1990 “Induction by antigen of 
intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo”]. The labelled cells 
were injected intravenously into naïve BALB/c mice 24 hours before IP sensitisation 
with whole OVA. 72 hours later lymph nodes from the mice were harvested and 
examined by flow cytometry.  As shown in figure 4, compared to mice receiving 
control IgG, there were increased numbers of DO11.10 cells producing IFNγ in mice 
given an anti-TF Ab, the frequency of which approached that seen in mice when LPS 
was used as adjuvant. Proliferation of these IFNγ-producing CD4+ cells was also 
increased compared to when OVA was administered with the control, but these data 
just failed to reach statistical significance. No differences in IL-4 production were 
noticed. No TF was found on CD4+ or CD8+ T cells isolated from spleen and lymph 
nodes of these mice as described (data not shown), indicating that the anti-TF Ab 
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was unlikely to be acting directly on the T cells and consistent with it having an 
influence on T cell priming via DC. 
To further investigate, a model of DC-dependent delayed type hypersensitivity was 
used.  For these experiments, a specific PAR-2 antagonist was used instead of the 
anti-TF Ab, so that only the signalling via PAR-2 was inhibited. C57BL/6 mice were 
injected with a PAR-2 antagonist peptide immediately prior to oxazolone 
sensitisation on the abdominal skin. Five days later mice were re-challenged with 
oxazolone and antigen-specific swelling calculated. As shown in figure 4C-D, mice 
given a PAR-2 antagonist at the time of sensitisation developed significantly greater 
antigen-specific swelling compared to control mice, consistent with the hypothesis 
that constitutive PAR-2 signalling modulates T cell priming.  
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Discussion  
TF expression has been previously defined on human DC in lymphoid follicles 17, DC 
derived from monocytes 4, 18 and on murine DC 5. In this report, we confirm TF 
expression by 10-15% of mouse BM-derived DC and show that this proportion and 
the level of TF expression was not influenced by addition of DEX or LPS in the final 2 
days of culture. However, the procoagulant activity was significantly different on 
these cell populations, with DEX-treated DC having approximately 5-fold less 
functional TF activity compared to untreated DC and 30-fold less than that of LPS-
treated DC (figure 2). These data suggest that DC have a mechanism to regulate the 
functional activity of TF, in line with their state of maturity, such that TF on immature 
DC exists predominantly in an encrypted or non-procoagulant state. 
The molecular basis of TF encryption /decryption remains enigmatic.  Potential 
mechanisms for decryption include an increase in the amount of procoagulant 
phosphatidylserine expressed on the cell membrane, and the conversion of Cys186-
Cys209 disulphide bonds by protein disulphide isomerase 19. We assessed the 
levels of both these on the surface of our DC and found no differences (data not 
shown).  Tissue factor pathway inhibitor can also the regulate the differential 
functions of TF 20, but there were no differences in the levels of murine tissue factor 
pathway inhibitor on all three types of our DC (data not shown), so the mechanism 
by which TF was regulated on these DC remains unclear   
 
Encrypted TF/FVIIa is known to signal through PAR-2 15, 21.  Using an inhibitory anti-
TF Ab, and a combination of PAR-2 agonists and antagonists, our data indicates that 
the encrypted TF on DEX-treated DC provides a signal through PAR-2 that 
suppresses CD4+ T cell proliferative responses, so that the anti-TF Ab or PAR-2 
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antagonist significantly enhanced CD4+ T cell proliferation after both allogeneic and 
antigen-specific stimulation.  In the presence of the anti-TF, these responses could 
be re-suppressed by pre-incubation of DC with the PAR-2 agonist. This mechanism 
was not apparent when the anti-TF Ab was used with untreated or LPS-treated DC, 
suggesting either that it was not operational on these cells, or that the effect was 
masked by the near maximal proliferative responses induced by these cells.  
In vivo, the anti-TF Ab enhanced the priming of naïve antigen-specific transgenic T 
cells to whole OVA (administered without an adjuvant), as shown by increased 
production of IFNγ and a trend towards increased proliferation.  The magnitude of 
the effect of anti-TF Ab was approximately 50% of control LPS adjuvant, indicating 
the potency of the TF-mediated suppression of priming in this system.  Additionally, 
the PAR-2 antagonist given to mice at the time of dermal priming to oxazolone 
enhanced the subsequent recall response, evident by a significant increase in the 
ear swelling on secondary challenge with the antigen.  In these experiments, a PAR-
2 agonist given during the priming phase had no significant impact on recall 
responses. These data suggest that the mechanism we have defined in vitro has a 
functional relevance in vivo. 
The effects of PAR-2 signalling on DEX-treated DC we report here are very different 
to those previously reported by others. Fields et al, described that PAR-2 signals 
were required for DC maturation during GM-CSF-induced outgrowth from BM cells 6, 
although these data have since been challenged 8. A number of studies have 
concluded that PAR-2 signalling enhances antigen uptake and trafficking by murine 
DC 8, and increases T cell activation in response to specific antigens 9, 10, 22.  In trying 
to reconcile our data with these, one obvious difference is that we have focussed on 
DEX-treated immature DC; the mechanism we describe appears irrelevant in mature 
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DC. It may also be relevant that others have compared responses in WT and PAR-2-
deficient mice and have addressed the effect of proteases other than TF/FVIIa.  
In summary, we report that the activity of TF, expressed on a subset of murine DC, 
varies with maturation state, such that TF on LPS-treated DC is procoagulant 
whereas on DEX-treated DC it appears to provide a tonic signal through PAR-2 that 
maintains an aspect of the low-immunogenic phenotype characteristic of these cells. 
This mechanism appears relevant in vivo, partially suppressing priming and 
subsequent recall responses. This novel role for TF/PAR signalling augments our 
understanding of DC function and highlights that manipulating this pathway might 
influence antigen-specific responses.  
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Figure legends 
 
Figure 1: Flow cytometric analysis of murine BM-derived DC to assess TF 
expression on DC at different states of functional maturity. 
 A: C57BL/6 BM cells were grown in GMCSF and DC harvested on day seven of 
culture before analysis by flow cytometry with the antibodies as indicated. Cells that 
were otherwise untreated are compared to those in which dexamtheasone (DEX -
1μM) or LPS (1μg/ml) were added into the culture for the final 48 or 24 hours 
respectively. Representative of 4 experiments. 
DEX-treated (B), untreated (C) and LPS-treated (D) DCs were harvested on day 
seven of culture and analysed for co-expression of CD11c and TF. Profiles show 
isotype control and specific binding. Numbers in quadrants represent percentage of 
positively stained cells within each quadrant. Representative profiles from one of four 
experiments. 
 
Figure 2: Analysis of TF function murine DC. 
A-B – Clotting assays with recalcified mouse plasma in presence of dexamethasone-
treated (DEX), untreated (UNTX) or LPS-treated (LPS) DCs or B16F10 tumour cells 
known to express high levels of surface TF (positive control in A).  The ordinate 
shows the time to clot in seconds (±SEM). Error bars in some columns are too small 
to see. In (B) respective DCs were incubated with increasing doses of anti-TF 
(closed triangles)) or rabbit control (open triangles) Ig.  
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C: Relative TF activity on dexamethasone (DEX)- and LPS-treated DC compared to 
untreated (UNTX) DC (=1) calculated from the clotting times from standard curves 
generated by titrating fixed concentrations of TF from mouse brain extract into the 
clotting assay. *P<0.01 compared to untreated.  
D: C57BL/6 male DEX-DCs were incubated with either medium, polyclonal rabbit 
anti-TF antibody or control rabbit Ig as indicated and co-cultured with purified Marilyn 
female CD4+ T cells. T cell response was measured by 3H incorporation on day three 
of culture. Graph shows mean +/- SEM of triplicate well. Compared to control Ig 
*p=0.05.  
E: Experiment similar to that in D, except DEX-treated BL/6 DC incubated with 
BALB/c CD4+ T cells. Compared to control Ig,  *p<0.002.  
F: As E, except untreated DC used as stimulators. P=NS 
G: As E, except CD8+ T cell used as responders. P=NS 
All data representative of three experiments. 
 
Figure 3: Experiments to determine PAR expression on mouse DC and 
interaction of TF with PAR-2 
A: RT-PCR analysis of RNA extracted from dexamethasone-treated (D), untreated 
(U) or LPS-treated (L) DC for expression of PAR-1-4. Control lane (N) contains RNA 
from DEX-treated cells without reverse transcriptase. Beta actin expression used as 
positive control for RNA integrity. 
B: Flow cytometric analysis of dexamethasone (DEX)-treated DC for expression of 
PARs 1-4 (open profiles). Shaded profiles show istotype control binding. 
C&D: dexamethasone (DEX)-treated DC were incubated with medium alone 
(medium), anti-TF Ab, or control rabbit Ig as indicated with or without additional 
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agonist peptides to activate PARs-1 and -4 (C) or PAR-2 (D), before co-culture with 
purified BALB/c CD4+ T cells.  Graphs show mean 3H-thymidine incorporation 
(±SEM) of triplicate wells on day five of culture. Representative of three experiments. 
p=NS all comparisons. 
E: As D but with additional control of dexamethasone (DEX)-treated DC incubated 
with a selective PAR-2 antagonist. Representative of three additional experiments. 
*p<0.05 
 
Figure 4: In vivo experiments demonstrating potential physiological role for 
TF/PAR-2 during sensitisation. 
A: 1x107 CFSE stained lymph node and spleen cells from naïve DO11.10 mice were 
injected intravenously into naïve BALB/c mice. 24 hours later mice were immunised 
with 5mg whole OVA given with either an anti-TF Ab (250µg) or control Ig or 25µl 
LPS (positive control).  Negative control mice received no OVA or LPS only. 72 
hours later the lymph node cells were harvested from individual mice and analysed 
for proliferation and cytokine production (IFN-γ and IL-4). Representative profiles 
from 1 of 9 mice from each group are shown. 
B: Experiment performed exactly as in A. The number of IFN-γ producing CFSE+ 
CD4+ T cells were enumerated from each mouse given OVA plus polyclonal Ig 
control (open bar), anti-TF (striped bar) or LPS (filled bar).  Fold increase was 
calculated as the ratio of this number for each mouse to the equivalent number of 
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CD4+ T cells enumerated for mice given LPS alone.  Mean and standard error was 
calculated for each group and is plotted as shown.  
C-E: Contact hypersensitivity was induced by sensitisation with 5% oxazolone on the 
shaved abdomen of C57BL/6 mice. 5 days later the mice were re-challenged with 
vehicle alone on the left ear and oxazolone on the right.  Graphs show difference in 
ear thickness between right and left ears 24 (C) and 48 (D) hours after re-challenge 
(n=12). Prior to initial sensitisation, mice received either a PAR-2 antagonist, PAR-2 
agonist or normal saline control IP. Data are expressed as an increase in ear 
thickness. Statistical analyses performed using two-way ANOVA with Bonferroni’s 
post test (* p<0.05 at both time points compared to saline) 
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Abstract 
Background: The precise function of tissue factor (TF) expressed by dendritic cells 
(DC) is uncertain. As well as initiating thrombin generation it can signal through 
protease activated receptor (PAR)-2 when complexed with factor VIIa. 
Methods: We investigated the expression and function of TF on mouse bone marrow 
(BM)-derived DC.  
Results: 20% of BM-derived DC expressed TF, which did not vary after incubation 
with LPS or dexamethasone (DEX). However, the procoagulant activity of DEX-
treated DC in recalcified plasma was 30 fold less than LPS-treated DC. In antigen-
specific and allogeneic T cell culture experiments, the TF on DEX-DC provided a 
signal through PAR-2, which contributed to the reduced ability of these cells to 
stimulate CD4+ T cell proliferation and cytokine-production.  In vivo, an inhibitory 
anti-TF Ab and a PAR-2 antagonist enhanced antigen-specific priming in two models 
where antigen was given without adjuvant, with an effect approximately 50% that 
seen with LPS, suggesting a similar mechanism was operational physiologically.   
Conclusions: These data suggest a novel TF and PAR-2 dependent mechanism on 
DEX-DC in vitro and unprimed DC in vivo that contributes to the low immunogenicity 
of these cells. Targeting this pathway has the potential to influence antigen-specific 
CD4+ T cell activation. 
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Introduction 
Initiation and propagation of the coagulation cascade in haemostasis and thrombosis 
is well characterised and results in the formation of a fibrin clot. Tissue factor (TF) is 
the physiological initiator of thrombin generation and is constitutively expressed on 
vascular adventitial cells, leading to the traditional concept that TF forms a 
‘haemostatic envelope’ to prevent bleeding from damaged vessels 1.  
TF can also be induced on inflammatory cells and has been implicated in the 
pathogenesis of a variety of diseases such as atherosclerosis, malignancy and Ab-
mediated rejection 2. Although some of these processes involve thrombosis, some of 
the effects of TF are fibrin-independent and involve signalling through protease 
activated receptors (PAR), which are cleaved by serine proteases to expose a neo-
N-terminal activating tethered ligand 3. Thrombin can cleave and activate PARs 1, 3 
& 4, whereas TF bound to factor VIIa (FVIIa) in a binary complex is capable of 
activating PAR-2 directly. PAR-2 is also cleaved by a number of other proteases 
including FXa, trypsin, proteinase 3 and mast cell tryptase. 
TF and PARs are expressed by a number of immune cells including monocytes, 
macrophages and DC 4. On antigen-primed DC, thrombin, via PAR-1 has a profound 
influence on migration through lymph nodes and subsequent spread of systemic 
inflammation in murine models of endotoxaemia and infection 5. Additionally, PAR-2 
signalling has been shown to enhance uptake of antigensDC antigen uptake,, 
trafficking and T cell activation by DC 6-10. 
In this paper, we have investigated the function of TF on mouse bone marrow (BM)-
derived DC, comparing DC outgrown under standard conditions with those incubated 
with either dexamethasone (DEX) or LPS. Our data suggests that, despite similar 
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expression levels of TF by all three, there is a hierarchy of procoagulant activity and 
TF  in particular expressedion by dexamethasone (DEX)-treated DC, on which TF 
appears to provide signalling through PAR-2 that to sustains the low immunogenicity 
of these cells DC. Based on additional data generated in vivo, we speculate that a 
similar mechanism operates physiologically to limit CD4+ T cell priming to specific 
antigens encountered in the absence of an adjuvant. 
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Methods  
Animals 
6-8 week old BALB/c (H-2d) and C57BL/6 (H-2b) mice were purchased from Harlan 
Laboratories. Two strains expressing transgenic T cell receptors (TCR) were used to 
assess antigen-specific responses, chosen because they were available within the 
Immunology Department. The first, Marilyn, has a transgenic TCR specific for male 
HY antigen restricted by MHC class II and the second, DO11.10 has a TCR that 
recognises an OVA peptide (OVA323-339) restricted by H-2Ad. Both mice were kind 
gifts from Drs Jian Guo Chai and Andrew George (Imperial College London).  All 
procedures were performed in accordance with the Home Office Animals (Scientific 
Procedures) Act of 1986.  
Cell isolation and T cell assays. 
BM-derived DC were cultured as described elsewhere 11.  Briefly cells were flushed 
out from the femurs and tibiae of mice and passed through a nylon cell strainer. Red 
blood cells were lysed using ammonium-chloride-potassium buffer. After washing, 
1x106/ml cells were seeded in RPMI growth medium plus 5% supernatant from a 
GM-CSF producing hybridoma cell line. On day 3, non adherent cells were discarded 
and fresh medium was added. In some cultures, either 1µM dexamethasone (DEX) 
(Sigma-Aldrich, UK) 12 or 1µg/ml LPS (Escherichia coli serotype 0128:B12) (Sigma-
Aldrich, UK) was added on days 5 or 6.  DCs were harvested on day 7.  
T cells were isolated from the spleen and lymph nodes (mesenteric, inguinal and 
axillary). Organs were passed through a nylon cell strainer and red blood cells were 
lysed as above. Splenocytes were incubated with an Ab cocktail supplied by 
Invitrogen containing rat anti-mouse Gr, CD16/32, MHCII and CD8 antibodies for 20 
min at 4°C before washing and incubation with sheep anti-rat magnetic beads for 
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negative selection according to manufacturer’s instructions. The resulting CD4+ T 
cells were 90-95% pure. 
To assess T cell proliferation against alloantigens, 2x105 BALB/c T cells were 
stimulated with 1x104 irradiated C57BL/6 DCs in 200µl complete medium unless 
otherwise stated. To assess antigen-specific proliferation, 2x105 female Marilyn 
CD4+ T cells were stimulated with 1x104 male C57BL/6 DCs in 200µl complete 
medium. In some assays, rabbit polyclonal anti-TF Ab (American Diagnostica) or 
control rabbit Ig were added at beginning. Proliferation was measured by adding 3H-
thymidine on day four of culture and harvesting 16 to 18 hours later to determine T 
cell proliferation as assessed by incorporated radioactivity.  
Flow cytometric analysis 
All flow cytometry was performed on a FACSCalibur flow cytometer and analysed 
using Cellquest (BD BioSciences, UK) or Flojo (Treestar, USA) software. For cell 
surface analysis, the following antibodies were used; rat anti-mouse CD4, CD8, (e-
Bioscience USA) FITC-CD80 (Serotec UK), FITC-CD86 (Becton Dickinson UK); 
hamster anti-mouse FITC-CD3, FITC-CD11c, FITC-MHC II (e-Bioscience USA); 
rabbit polyclonal anti-TF, anti-TFPI (both American Diagnostica), PAR-3, PAR-4 
(Santa Cruz USA); mouse anti-PAR-1 (Becton Dickinson), PAR-2 (Santa Cruz). 
Where appropriate, the following second layers were used; Swine anti-rabbit FITC-Ig 
(Dako, Denmark); Goat anti-rabbit FITC-Ig, anti-rabbit PE-Ig (Sigma-Aldrich UK), 
anti-mouse FITC IgG (Dako); mouse anti-rat FITC-Ig (e-Bioscience). 2x105 cells 
were analysed immediately or fixed in 2% paraformaldehyde in PBS and analysed 
within three days. 
Intracellular cytokine staining as performed as previously described 13.  Briefly, cells 
were stimulated with 50ng/ml PMA (Sigma-Aldrich, UK) plus 500ng/ml ionomycin 
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(Calbiochem, Germany) for 4 hours, with 10µg/ml brefeldin A (Sigma-Aldrich) for the 
final 2 hours. All washes and incubations were done in buffer containing 0.5% 
Saponin (Sigma-Aldrich). Cells were stained with rat anti-IFNγ, IL-4 or IL-10 (all from 
BD Pharmingen USA) 
RNA extraction and RT-PCR 
Between 5x106 and 1x107 cells were washed thoroughly with PBS before RNA was 
extracted using phenol and chloroform and re-suspended in RNAse-free water 
(Sigma-Aldrich).  RNA was assessed using agarose gel analysis and Quanti-iT 
Ribogreen RNA reagent and kit (Invitrogen, UK). RT-PCR was peformed using 
reagents from Applied Biosystems, USA, including primers for PARs 1-4 and beta-
actin. All PCR products were run on 1% agarose gel. 
Clotting Assay  
Mouse acetone brain extract (Sigma, UK), used as a standardized source of TF and 
all other reagents were suspended in 50mM Tris-HCL, 150 mM NaCl and 1 mg/ml 
human albumin pH 7.4. For test samples, cells were suspended at a concentration of 
1x107/ml. Serial dilutions of brain extract (in 80μl) or 1x107 cells /ml (80μl) were 
mixed in a glass tube with 80μl phospholipid and 80μl pooled normal mouse plasma 
at 37°C for one minute. To start the clotting assay 80μl 65mM CaCl2 was added, 
and, whilst being continuously agitated, the time for a clot to form in the tube was 
measured. In some assays, rabbit polyclonal anti-TF Ab or control rabbit Ig were 
added at beginning. All samples performed in triplicate. A standard curve generated 
from the TF in mouse brain extract was used to measure relative TF function in the 
test samples.  
In vivo antigen specific T cell sensitisation 
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Cells from lymph nodes and spleen of naive DO11.10 mice were labelled with 2.5µM 
CFSE (Cambridge Biosciences, UK) using standard protocols.  1x107 cells were 
injected into the tail vein of BALB/c mice.  24 hours later, the mice were given an i.p. 
injection of either saline, 250µg anti-TF Ab 14, control rabbit Ig, 25µg LPS 
(Escherichia coli serotype 0127:B8) (Sigma-Aldrich, UK)  or LPS alone followed by 
5mg whole OVA.  72 hours later, lymph node (cervical, axillary, brachial and 
inguinal) cells were harvested for analysis of proliferation and IFN-γ, IL-4 and IL-10 
production by flow cytometry. 
Contact sensitivity responses 
On day 0, C57BL/6 mice were sensitised by application of 5% oxazalone in ethanol 
and acetone (4:1, 50ul) to the shaved abdomen. At the same time mice were 
injected i.p. with either 100µl saline control, 1uM/kg PAR 2 agonist or 100uM/kg 
PAR-2 antagonist. Mice were re-challenged on day 5 by applying 1% oxazolone in 
olive oil and acetone (4:1, 10ul) to the right ear, whereas the left ear was painted 
with vehicle alone. Ear thickness was measured using a digitial micrometer. 
Measurements were done on day 5 as a baseline and then 24 and 48 hours 
following ear painting. 
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Results 
 
TF expression and procoagulant function on in-vitro cultured DC 
C57BL/6 BM-derived DC (>85% CD11c+) were examined by flow cytometry.  Figure 
1 illustrates the expression of MHC class II, CD80 and CD86 by cells grown under 
three different conditions. As expected, DEX-treated DC expressed low levels of 
MHC II and co-stimulatory molecules whereas LPS-treated DC had higher 
expression.  DC cultured without either DEX or LPS (‘untreated’) had an intermediate 
phenotype. Subpopulations of DC from all three conditions expressed detectable TF 
antigen on their cell surface, representing 15-20% of the CD11c+ cells, with similar 
population MFI (figure 1B-D), suggesting similar levels of TF expression.  Similar 
results were obtained with DC grown from BALB/c mice (data not shown).  
In clotting assays using re-calcified mouse plasma, addition of all three DC 
populations promoted shorter clotting times compared to the ‘no cells’ control, with a 
hierarchy of clotting times (LPS<untreated<DEX) (figure 2A), each of which was 
prolonged by an inhibitory anti-TF Ab (figure 2B) suggesting that there were 
significantly different levels of procoagulant TF present on each type of DC. This was 
confirmed when the relative TF procoagulant activity on each was calculated (Figure 
2C).  In these experiments, the time to clot spontaneously in glass tubes (‘no cells’ in 
Figure 2A) represents the clotting induced by the (TF-independent) contact activated 
pathway. These data indicated that a greater proportion of TF on DEX-treated DC 
was in the non-procoagulant or ‘encrypted’ form.  There were no detectable 
differences in annexin V binding, protein disulphide isomerase or murine tissue 
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factor pathway inhibitor expression by any of the DC used in these assays (data not 
shown).  
 
Biological activity of TF on DEX-treated DC  
To investigate whether TF on DEX-treated DC had a biological function, male DCs 
were co-cultured with naïve CD4+ T cells from female Marilyn mice, which possess a 
transgenic TCR that recognises the male HY antigen restricted by MHC class II. 
Compared to DEX-treated DC incubated with isotype control Ig, DC incubated with 
inhibitory anti-TF Ab stimulated significantly greater proliferation (figure 2D). These 
experiments were repeated with allogeneic DC and WT CD4+ T cells, with similar 
results (figure 2E), suggesting that the effect was not due to antigen processing. The 
same Ab did not enhance the near-maximal proliferation induced by untreated DC 
(figure 2F) and had no impact on proliferation of CD8+ T cells induced by DEX-
treated DC (figure 2G). These results indicated that inhibiting TF on DEX-DC 
specifically enhanced proliferation by CD4+ T cells and suggested that the TF on 
DEX-DC was acting to limit the capacity of these cells to induce CD4+ T cell 
proliferation.  
The TF- FVIIa complex can cleave and activate PAR-2 signalling 15. Analysis of PAR 
expression by DEX-DC revealed transcripts for all PARs (figure 3A), but only PAR-2 
and PAR-4 were detectable on the cell surface by flow cytometry (figure 3B), which 
may reflect known differences in the importance of mRNA stabilisation for expression 
of different PARs 16. To address whether the effect of TF was due to signalling 
through PAR, agonist or antagonist peptides were added to DEX-DCs, prior to co-
culture with CD4+ T cells. Figures 3C&D show that, in contrast to when PAR-1 or -4 
agonists were used, a selective PAR-2 agonist inhibited the effect of the anti-TF Ab, 
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indicating that PAR-2 activation was able to compensate for the inhibition of TF when 
Ab was present.  In contrast, a PAR-2 antagonist enhanced the proliferative capacity 
of DEX-treated DC to the same extent as the anti-TF Ab (figure 3E), suggesting that 
it had the same functional effect as the Ab.  These data are consistent with the 
hypothesis that the (mostly) encrypted TF on DEX-treated DC influences the 
capacity to stimulate T cells through activation of PAR-2. 
 
Inhibition of TF/PAR-2 signaling enhances T cell priming in vivo 
To assess whether any of this was relevant in vivo, lymph node and spleen cells 
from naïve DO11.10 mice were isolated and CFSE labelled. T cells from these mice 
possess a transgenic T cell receptor that recognises an OVA peptide (OVA323-339) 
restricted by H-2Ad [372- Murphy KM Science 1990 “Induction by antigen of 
intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo”]. The labelled cells 
were injected intravenously into naïve BALB/c mice 24 hours before IP sensitisation 
with whole OVA. 72 hours later lymph nodes from the mice were harvested and 
examined by flow cytometry.  As shown in figure 4, compared to mice receiving 
control IgG, there were increased numbers of DO11.10 cells producing IFNγin mice 
given an anti-TF Ab, the frequency of which approached that seen in mice when LPS 
was used as adjuvant. Proliferation of these IFNγ-producing CD4+ cells was also 
increased compared to when OVA was administered with the control, but these data 
just failed to reach statistical significance. No differences in IL-4 production were 
noticed. No TF was found on CD4+ or CD8+ T cells isolated from spleen and lymph 
nodes of these mice as described (data not shown), indicating that the anti-TF Ab 
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was unlikely to be acting directly on the T cells and consistent with it having an 
influence on T cell priming via DC. 
To further investigate, a model of DC-dependent delayed type hypersensitivity was 
used.  For these experiments, a specific PAR-2 antagonist was used instead of the 
anti-TF Ab, so that only the signalling via PAR-2 was inhibited. C57BL/6 mice were 
injected with a PAR-2 antagonist peptide immediately prior to oxazolone 
sensitisation on the abdominal skin. Five days later mice were re-challenged with 
oxazolone and antigen-specific swelling calculated. As shown in figure 4C-D, mice 
given a PAR-2 antagonist at the time of sensitisation developed significantly greater 
antigen-specific swelling compared to control mice, consistent with the hypothesis 
that constitutive PAR-2 signalling modulates T cell priming.  
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Discussion  
TF expression has been previously defined on human DC in lymphoid follicles 17, DC 
derived from monocytes 4, 18 and on murine DC 5. In this report, we confirm TF 
expression by 10-15% of mouse BM-derived DC and show that this proportion and 
the level of TF expression was not influenced by addition of DEX or LPS in the final 2 
days of culture. However, the procoagulant activity was significantly different on 
these cell populations, with DEX-treated DC having approximately 5-fold less 
functional TF activity compared to untreated DC and 30-fold less than that of LPS-
treated DC (figure 2). These data suggest that DC have a mechanism to regulate the 
functional activity of TF, in line with their state of maturity, such that TF on immature 
DC exists predominantly in an encrypted or non-procoagulant state. 
The molecular basis of TF encryption /decryption remains enigmatic.  Potential 
mechanisms for decryption include an increase in the amount of procoagulant 
phosphatidylserine expressed on the cell membrane, and the conversion of Cys186-
Cys209 disulphide bonds by protein disulphide isomerase 19. We assessed the 
levels of both these on the surface of our DC and found no differences (data not 
shown).  Tissue factor pathway inhibitor can also the regulate the differential 
functions of TF 20, but there were no differences in the levels of murine tissue factor 
pathway inhibitor on all three types of our DC (data not shown), so the mechanism 
by which TF was regulated on these DC remains unclear   
 
Encrypted TF/FVIIa is known to signal through PAR-2 15, 21.  Using an inhibitory anti-
TF Ab, and a combination of PAR-2 agonists and antagonists, our data indicates that 
the encrypted TF on DEX-treated DC provides a signal through PAR-2 that 
suppresses CD4+ T cell proliferative responses, so that the anti-TF Ab or PAR-2 
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antagonist significantly enhanced CD4+ T cell proliferation after both allogeneic and 
antigen-specific stimulation.  In the presence of the anti-TF, these responses could 
be re-suppressed by pre-incubation of DC with the PAR-2 agonist. This mechanism 
was not apparent when the anti-TF Ab was used with untreated or LPS-treated DC, 
suggesting either that it was not operational on these cells, or that the effect was 
masked by the near maximal proliferative responses induced by these cells.  
In vivo, the anti-TF Ab enhanced the priming of naïve antigen-specific transgenic T 
cells to whole OVA (administered without an adjuvant), as shown by increased 
production of IFNγ and a trend towards increased proliferation.  The magnitude of 
the effect of anti-TF Ab was approximately 50% of control LPS adjuvant, indicating 
the potency of the TF-mediated suppression of priming in this system.  Additionally, 
the PAR-2 antagonist given to mice at the time of dermal priming to oxazolone 
enhanced the subsequent recall response, evident by a significant increase in the 
ear swelling on secondary challenge with the antigen.  In these experiments, a PAR-
2 agonist given during the priming phase had no significant impact on recall 
responses. These data suggest that the mechanism we have defined in vitro has a 
functional relevance in vivo. 
The effects of PAR-2 signalling on DEX-treated DC we report here are very different 
to those previously reported by others. Fields et al, described that PAR-2 signals 
were required for DC maturation during GM-CSF-induced outgrowth from BM cells 6, 
although these data have since been challenged 8. A number of studies have 
concluded that PAR-2 signalling enhances murine DC antigen uptake and trafficking 
by murine DC 8, and increases T cell activation in response to specific antigens 9, 10, 
22.  In trying to reconcile our data with these, one obvious difference is that we have 
focussed on DEX-treated immature DC; the mechanism we describe appears 
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irrelevant in mature DC. It may also be relevant that others have compared 
responses in WT and PAR-2-deficient mice and have addressed the effect of 
proteases other than TF/FVIIa.  
In summary, we report that the activity of TF, expressed on a subset of murine DC, 
varies with maturation state, such that TF on LPS-treated DC is procoagulant 
whereas on DEX-treated DC it appears to provide a tonic signal through PAR-2 that 
maintains an aspect of the low-immunogenic phenotype characteristic of these cells. 
This mechanism appears relevant in vivo, partially suppressing priming and 
subsequent recall responses. This novel role for TF/PAR signalling augments our 
understanding of DC function and highlights that manipulating this pathway might 
influence antigen-specific responses.  
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Figure legends 
 
Figure 1: Flow cytometric analysis of murine BM-derived DC to assess TF 
expression on DC at different states of functional maturity. 
 A: C57BL/6 BM cells were grown in GMCSF and DC harvested on day seven of 
culture before analysis by flow cytometry with the antibodies as indicated. Cells that 
were otherwise untreated (UNTX) are compared to those in which dexamtheasone 
(DEX -1μM) or LPS (1μg/ml) were added into the culture for the final 48 or 24 hours 
respectively. Representative of 4 experiments. 
DEX-treated (B), untreated (C) and LPS-treated (D) DCs were harvested on day 
seven of culture and analysed for co-expression of CD11c and TF. Profiles show 
isotype control and specific binding. Numbers in quadrants represent percentage of 
positively stained cells within each quadrant. Representative profiles from one of four 
experiments. 
 
Figure 2: Functional aAnalysis of TF function murine DC. 
A-B – Clotting assays with recalcified mouse plasma in presence of dexamethasone-
treated (DEX), untreated (UNTX) or LPS-treated (LPS) DCs or B16F10 tumour cells 
known to express high levels of surface TF (positive control in A).  The ordinate 
shows the time to clot in seconds (±SEM). Error bars in some columns are too small 
to see. In (B) respective DCs were incubated with increasing doses of anti-TF 
(closed triangles)) or rabbit control (open triangles) Ig.  
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C: Relative TF activity on dexamethasone (DEX)- and LPS-treated DC compared to 
untreated (UNTX) DC (=1) calculated from the clotting times from standard curves 
generated by titrating fixed concentrations of TF from mouse brain extract into the 
clotting assay. *P<0.01 compared to untreated.  
D: C57BL/6 male DEX-DCs were incubated with either medium, polyclonal rabbit 
anti-TF antibody or control rabbit Ig as indicated and co-cultured with purified Marilyn 
female CD4+ T cells. T cell response was measured by 3H incorporation on day three 
of culture. Graph shows mean +/- SEM of triplicate well. Compared to control Ig 
*p=0.05.  
E: Experiment similar to thatAs in AD, except DEX-treated BL/6 DC incubated with 
BALB/c CD4+ T cells. Compared to control Ig,  *p<0.002.  
F: As E, except untreated DC used as stimulators. P=NS 
G: As E, except CD8+ T cell used as responders. P=NS 
All data representative of three experiments. 
 
Figure 3: TF/PAR-2Experiments to determine PAR expression on mouse DC 
and interaction of TF with PAR-2 
A: RT-PCR analysis of RNA extracted from dexamethasone-treated (D), untreated 
(U) or LPS-treated (L) DC for expression of PAR-1-4. Control lane (N) contains RNA 
from DEX-treated cells without reverse transcriptase. Beta actin expression used as 
positive control for RNA integrity. 
B: Flow cytometric analysis of dexamethasone (DEX)-treated DC for expression of 
PARs 1-4 (open profiles). Shaded profiles show istotype control binding. 
C&D: dexamethasone (DEX)-treated DC were incubated with medium alone 
(medium), anti-TF Ab, or control rabbit Ig as indicated with or without additional 
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agonist peptides to activate PARs-1 and -4 (C) or PAR-2 (D), before co-culture with 
purified BALB/c CD4+ T cells.  Graphs show mean 3H-thymidine incorporation 
(±SEM) of triplicate wells on day five of culture. Representative of three experiments. 
p=NS all comparisons. 
E: As D but with additional control of dexamethasone (DEX)-treated DC incubated 
with a selective PAR-2 antagonist. Representative of three additional experiments. 
*p<0.05 
 
Figure 4: In vivo experiments demonstrating potential physiological role for 
TF/PAR-2 during sensitisation. 
A: 1x107 CFSE stained lymph node and spleen cells from naïve DO11.10 mice were 
injected intravenously into naïve BALB/c mice. 24 hours later mice were immunised 
with 5mg whole OVA given with either an anti-TF Ab (250µg) or control Ig or 25µl 
LPS (positive control).  Negative control mice received no OVA or LPS only. 72 
hours later the lymph node cells were harvested from individual mice and analysed 
for proliferation and cytokine production (IFN-γ and IL-4). Representative profiles 
from 1 of 9 mice from each group are shown. 
B: Experiment performed exactly as in A. The number of IFN-γ producing CFSE+ 
CD4+ T cells were enumerated from each mouse given OVA plus polyclonal Ig 
control (open bar), anti-TF (striped bar) or LPS (filled bar).  Fold increase was 
calculated as the ratio of this number for each mouse to the equivalent number of 
Page 51 of 52 Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 24 
CD4+ T cells enumerated for mice given LPS alone.  Mean and standard error was 
calculated for each group and is plotted as shown.  
C-E: Contact hypersensitivity was induced by sensitisation with 5% oxazolone on the 
shaved abdomen of C57BL/6 mice. 5 days later the mice were re-challenged with 
vehicle alone on the left ear and oxazolone on the right.  Graphs show difference in 
ear thickness between right and left ears 24 (C) and 48 (D) hours after re-challenge 
(n=12). Prior to initial sensitisation, mice received either a PAR-2 antagonist, PAR-2 
agonist or normal saline control IP. Data are expressed as an increase in ear 
thickness. Statistical analyses performed using two-way ANOVA with Bonferroni’s 
post test (* p<0.05 at both time points compared to saline) 
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